Insulin Glulisine in Diabetes Mellitus, Type 2

PHASE3CompletedINTERVENTIONAL
Enrollment

311

Participants

Timeline

Start Date

November 30, 2004

Primary Completion Date

November 30, 2007

Conditions
Diabetes Mellitus, Type 2
Interventions
DRUG

Insulin Glulisine

insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal

DRUG

Insulin Therapy

NPH (70%) plus regular insulin or insulin aspart (30%)

DRUG

Insulin Glargine

1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG

Trial Locations (15)

Unknown

Sanofi-Aventis, Meyrin

Sanofi-Aventis, Guildford

Sanofi-Aventis, North Ryde

Sanofi-Aventis, Brussels

Sanofi-Aventis, Prague

Sanofi-Aventis, Paris

Sanofi-Aventis, Berlin

Sanofi-Aventis, Milan

Sanofi-Aventis, Gouda

Sanofi-Aventis, Warsaw

Sanofi-Aventis, Porto Salvo

Sanofi-aventis, Bucharest

Sanofi-Aventis, Bratislava

Sanofi-Aventis, Barcelona

Sanofi-Aventis, Stockholm

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Sanofi

INDUSTRY